Abbott presents Oncodetect data at ESMO showing 30% sensitivity improvement for colorectal cancer recurrence detection

Abbott presented new clinical data at the ESMO Congress on its Oncodetect whole-genome sequencing test for colorectal cancer, showing a 30% absolute improvement in sensitivity for detecting cancer recurrence within two years of surgery.

Detected & updated continuously · Source: Nebula